CTLA-4 (CD152) controls homeostasis and suppressive capacity of regulatory T cells in mice. Arthritis Rheum. 60 , 123–132 (2009). Article CAS Google Scholar ...
As I understand it, COYA 301 promotes Treg function, and CTLA-4 Ig keeps Tregs from senescence and apoptosis, enhancing the therapeutic window. These are the results seen with LD IL-2 + CTLA-4 Ig ...
Cytotoxic T-lymphocyte antigen 4 (CTLA-4) is a cell surface molecule with immunosuppressive function involved in T-cell immune regulation and proliferation. Researchers from Shanghai Junshi ...
Foxp3 may steer T cells down specific pathways by amplifying and stabilizing features advantageous to Treg differentiation, such as CD25 and CTLA-4 expression, or by repressing features ...
Coya Therapeutics, Inc. (Nasdaq: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance regu ...
CS2009是一款同时靶向PD-1、CTLA-4和VEGFA的药物，具有潜在同类首创的作用机理。 CS2009拥有平衡的抗PD-1和抗CTLA-4亲和力，可以同时结合PD-1、CTLA-4及VEGFA ...
6d
Will present initial Phase 1C dose escalation data for vilastobart (XTX101), a tumor-activated, Fc-enhanced anti-CTLA-4, in combination with ...
Adagene (ADAG) announced data at the SITC 39th Annual Meeting, taking place in Houston, Nov. 6 – 10, 2024. The two poster presentations ...
Tfr同时表达Treg主调控因子Foxp3和其他Treg相关分子，如CD25和CTLA-4。Tfr表达异常可能导致免疫耐受的破坏，进而诱导自身免疫性疾病的免疫发病机制。
Agenus Inc. (“Agenus”) (Nasdaq: AGEN), a leader in developing novel immunological agents to treat various cancers, today announced the presentation of new data on two of its promising investigational ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback